Kane Biotech Inc.
KNE.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -166.27% | 220.19% | 219.94% | 231.00% | 222.17% |
| Total Depreciation and Amortization | -12.61% | -11.40% | -9.90% | -9.00% | -5.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.62% | -504.15% | -544.64% | -688.09% | -860.30% |
| Change in Net Operating Assets | 51.74% | -305.40% | -244.58% | -219.09% | -265.16% |
| Cash from Operations | 41.03% | -95.51% | -95.61% | -163.12% | -132.12% |
| Capital Expenditure | 8.84% | -126.42% | -167.65% | -994.44% | -1,408.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -99.26% | -- | -- | -- | -- |
| Other Investing Activities | -107.85% | -129.77% | -7.27% | 1,478.45% | 1,086.01% |
| Cash from Investing | -100.55% | 364.13% | 1,341.56% | 9,861.64% | 7,264.33% |
| Total Debt Issued | 0.00% | -- | -- | -100.00% | -1.18% |
| Total Debt Repaid | 91.34% | -918.06% | -1,279.81% | -1,775.17% | -2,734.04% |
| Issuance of Common Stock | 660.03% | 398.46% | 49.07% | -40.12% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.60% | -1,082.98% | -822.18% | -701.81% | -2,273.26% |
| Cash from Financing | 152.67% | -763.44% | -451.70% | -448.25% | -997.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 559.91% | -267.38% | -292.05% | -389.91% | 91.21% |